根据名称进行药物检索

Abacavir, dolutegravir, and lamivudine与高胆固醇 (血脂蛋白过多症、高甘油三酯血症,、谷固醇血症)

Abacavir, dolutegravir, and lamivudine与高胆固醇 (血脂蛋白过多症、高甘油三酯血症,、谷固醇血症)安全配伍检测的结果。

检测结果:

Abacavir, dolutegravir, and lamivudine <> 高胆固醇 (血脂蛋白过多症、高甘油三酯血症,、谷固醇血症)

现实性: 03.07.2019 评论家: 医学副博士Shkutko P.M., in

通过权威的信息来源 Drugs.com、Rxlist.com、Webmd.com、Medscape.com，在进行所选药物与这种食物或生活方式互相作用检测时，发现一些会产生负面影响或对身体危害的禁忌症及副作用。

用户:

该逆转录酶抑制剂、去羟肌苷(I),扎西他濱(hm),司他夫定(d4T)和拉米夫定(3TC)，可能会导致胰腺炎。发生率一般较低，但是大约7%与I，以及多达15%的儿童患者给予3TC. 史的患者或已知的危险因素胰腺炎，如酗酒或血症、应密切监测在治疗过程中与这些试剂。治疗应该终止的第一个迹象或症状暗示的胰腺炎(例如，恶心、呕吐、腹痛、高澱粉血症与血糖異常，上升的甘油三酯，降低血钙)，而最好永久性地终止，如果临床胰腺炎的发展。

医界专家:

来源

"Product Information. Zerit (stavudine)." Bristol-Myers Squibb, Princeton, NJ.
van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, Ingrand D, Weber J, Hill A, McDade H, et al "Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study." J Infect Dis 171 (1995): 1166-71
Dolin R, Lambert JS, Morse GD, et al "2',3'-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990): s540-51
van Leeuwen R, Lange JM, Hussey EK, Donn KH, Hall ST, Harker AJ, Jonker P, Danner SA "The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study." AIDS 6 (1992): 1471-5
Yarchoan R, Mitsuya H, Pluda JM, et al "The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990): s522-33
Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993): S63-8
Matthews SJ, Cersosimo RJ, Spivack ML "Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease." Pharmacotherapy 11 (1991): 419-49
"Product Information. Epivir (lamivudine)." Glaxo Wellcome, Research Triangle Park, NC.
Shelton MJ, O'Donnell AM, Morse GD "Didanosine." Ann Pharmacother 26 (1992): 660-70
Whittington R, Brogden RN "Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)." Drugs 44 (1992): 656-83
"Product Information. Videx (didanosine)." Bristol-Myers Squibb, Princeton, NJ.
"Product Information. HIVID (zalcitabine)." Roche Laboratories, Nutley, NJ.
Grasela TH, Walawander CA, Beltangady M, Knupp CA, Martin RR, Dunkle LM, Barbhaiya RH, Pittman KA, Dolin R, Valentine FT, "Analysis of potential risk factors associated with the development of pancreatitis in phase i patients with AIDS or AIDS-related complex receiving didanosine." J Infect Dis 169 (1994): 1250-5
Schindzielorz A, Pike I, Daniels M, Pacelli L, Smaldone L "Rates and risk factors for adverse events associated with didanosine in the expanded access program." Clin Infect Dis 19 (1994): 1076-83
Moore RD, Fortgang I, Keruly J, Chaisson RE "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med 101 (1996): 34-40
Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994): 924-30
Bouvet E, Casalino E, Prevost MH, Vachon F "Fatal case of 2',3'-dideoxyinosine-associated pancreatitis." Lancet 336 (1990): 1515
Maxson CJ, Greenfield SM, Turner JL "Acute pancreatitis as a common complication of 2',3'-dideoxyinosine therapy in the acquired immunodeficiency syndrome." Am J Gastroenterol 87 (1992): 708-13